Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

In the S0313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radiotherapy (IFRT) in patients with limited-stage aggressive B-cell non-Hodgkin lymphom...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Persky, Daniel O., Miller, Thomas P., Unger, Joseph M., Spier, Catherine M., Puvvada, Soham, Stea, B. Dino, Press, Oliver W., Constine, Louis S., Barton, Kevin P., Friedberg, Jonathan W., LeBlanc, Michael, Fisher, Richard I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2015
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4287635/
https://ncbi.nlm.nih.gov/pubmed/25395425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-584623
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller